Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO

Blood

Volumn 120, Issue 16, 2012, Pages 3246-3255

  Kremer, Anita N ^a   Van Der Meijden, Edith D ^a   Honders, Maria W ^a   Goeman, Jelle J ^a   Wiertz, Emmanuel J H J ^b   Falkenburg, J H Frederik ^a   Griffioen, Marieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; HLA DM ANTIGEN; HLA DO ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VIVO STUDY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

EID: 84868139454     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-399311     Document Type: Article

References (48)

1. Toes RE, Schoenberger SP, van d V, Offringa R, Melief CJ. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol. 1998;10(6):443-448. (Pubitemid 28564373)
2. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300(5617):337-339. (Pubitemid 36433726)
3. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852-856. (Pubitemid 36254145)
4. Faber LM, van Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JH. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood. 1995;86(7):2821-2828.
5. Michalek J, Collins RH, Durrani HP, et al. Definitive separation of graft-versus-leukemia-and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A. 2003;100(3):1180-1184. (Pubitemid 36183976)
6. Rutten CE, van Luxemburg-Heijs SA, Griffioen M, et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia. 2008;22(7):1387-1394. (Pubitemid 352006083)
7. Dodi IA, Van RF, Forde HC, et al. CD4 (+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy. 2002;4(4):353-363.
8. Stevanovic S, Griffioen M, Nijmeijer BA, et al. Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia. 2012;26(2):312-22.
9. Soiffer RJ, Alyea EP, Hochberg E, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8(11):625-632. (Pubitemid 35446754)
10. Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood. 2007;109(1):374-382. (Pubitemid 46053080)
11. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev. 2005;207:145-157. (Pubitemid 41415014)
12. Dongre AR, Kovats S, de Roos P, et al. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol. 2001;31(5):1485-1494. (Pubitemid 32454696)
13. Muntasell A, Carrascal M, Alvarez I, et al. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands. J Immunol. 2004;173(2):1085-1093. (Pubitemid 38924283)
14. Stumpf AN, van der Meijden ED, van Bergen CA, et al. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood. 2009;114(17):3684-3692.
15. *0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunol Immunother. 2011;60(3):327-337.
16. Harris PE, Maffei A, Colovai AI, et al. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Blood. 1996;87(12):5104-5112. (Pubitemid 26189851)
17. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993;178(1):27-47. (Pubitemid 23173241)
18. Newcomb JR, Cresswell P. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers. J Immunol. 1993;150(2):499-507. (Pubitemid 23133625)
19. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science. 1997;278(5335):106-109.
20. van Ham SM, Tjin EP, Lillemeier BF, et al. HLA-DO is a negative modulator of HLA-DMmediated MHC class II peptide loading. Curr Biol. 1997;7(12):950-957. (Pubitemid 28017072)
21. Fallas JL, Yi W, Draghi NA, O'Rourke HM, Denzin LK. Expression patterns of H2-O in mouse B cells and dendritic cells correlate with cell function. J Immunol. 2007;178(3):1488-1497. (Pubitemid 46156830)
22. Griffioen M, van der Meijden ED, Slager EH, et al. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci U S A. 2008;105(10):3837- 3842. (Pubitemid 351723486)
23. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood. 2002;99(8):3027-3032. (Pubitemid 34525395)
24. Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med. 2009;206(7):1525-1534.
25. Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity. 2000;13(4):517-527.
26. Griffioen M, van Egmond HM, Barnby-Porritt H, et al. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica. 2008;93(10):1535-1543.
27. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008;24(13):1547-1548. (Pubitemid 351911712)
28. Sloan VS, Cameron P, Porter G, et al. Mediation by HLA-DM of dissociation of peptides from HLADR. Nature. 1995;375(6534):802-806.
29. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity. 1995;3(2):197-205.
30. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell. 1995;82(1):155-165.
31. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med. 1996;184(5):1747-1753. (Pubitemid 26404466)
32. Brocke P, Garbi N, Momburg F, Hammerling GJ. HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr Opin Immunol. 2002;14(1):22-29. (Pubitemid 34085103)
33. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science. 1996;274(5287):618-620. (Pubitemid 26360442)
34. Kropshofer H, Vogt AB, Moldenhauer G, et al. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 1996;15(22):6144-6154. (Pubitemid 26397886)
35. Jensen PE, Weber DA, Thayer WP, Chen X, Dao CT. HLA-DM and the MHC class II antigen presentation pathway. Immunol Res. 1999;20(3):195-205. (Pubitemid 30119567)
36. Mempel TR, Henrickson SE, von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature. 2004;427(6970):154-159. (Pubitemid 38094955)
37. Sant AJ, Chaves FA, Jenks SA, et al. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II: peptide complexes. Immunol Rev. 2005;207:261-278. (Pubitemid 41415023)
38. Pashine A, Busch R, Belmares MP, et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity. 2003;19(2):183-192. (Pubitemid 37011333)
39. Belmares MP, Busch R, Wucherpfennig KW, McConnell HM, Mellins ED. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol. 2002;169(9):5109-5117. (Pubitemid 35217180)
40. Denzin LK, Fallas JL, Prendes M, Yi W. Right place, right time, right peptide: DO keeps DM focused. Immunol Rev. 2005;207:279-292. (Pubitemid 41415024)
41. Liljedahl M, Winqvist O, Surh CD, et al. Altered antigen presentation in mice lacking H2-O. Immunity. 1998;8(2):233-243. (Pubitemid 28123750)
42. Alfonso C, Williams GS, Han JO, et al. Analysis of H2-O influence on antigen presentation by B cells. J Immunol. 2003;171(5):2331-2337. (Pubitemid 37025539)
43. van Ham M, van Lith M, Lillemeier B, et al. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J Exp Med. 2000;191(7):1127-1136.
44. Perraudeau M, Taylor PR, Stauss HJ, et al. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice. Eur J Immunol. 2000;30(10):2871-2880.
45. Falkenburg JH, Warren EH. Graft versus leukemia reactivity after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(1):S33-S38.
46. Ferrara JL, Levine JE, Reddy P, Holler E. Graftversushost disease. Lancet. 2009;373(9674):1550-1561.
47. Walter W, Scheuer C, Lingnau K, et al. H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cytokines. Immunogenetics. 2000;51(10):794-804. (Pubitemid 30612043)
48. Chamuleau ME, Souwer Y, van Ham SM, et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 2004;64(16):5546-5550. (Pubitemid 39095546)